Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-117 vs AD-117A pharmacokinetics in healthy volunteers
NCT07152873Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-117 in mixed dyslipidemia (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Plasma Concentration-Time Curve During Dosing Interval at 72 hours. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
AD-117
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT07152873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152873.